RUNX3 and gastric cancer: Mechanistically and functionally, circREPS2 directly targets miR-558 and leads to an increase in the expression of RUNX3 (as a tumor suppressor) to inactivate the Wnt/β-catenin pathway and a decrease in β-catenin levels, thereby suppressing GC progression.